Table 2

Ongoing phase I/II trials involving drugs with known inhibitory activity of NTRK-related kinases

NCT/EudraCT numberTitleDrugTargetsPhasesPatientsStart date
NCT02219711Phase 1/1b study of MGCD516 in patients with advanced cancerMGCD516MET, AXL, c-kit, MER, DDR2,
VEGFR, PDGFR, RET, Trk, Eph
1120August 2014
NCT02568267Basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors harboring NTRK1/2/3, ROS1, or ALK gene rearrangements (fusions)Entrectinib
(RXDX-101)
TrkA, TrkB, TrkC,
ROS1, ALK
2300October 2015
NCT02097810Study of oral RXDX-101 in adult patients with locally advanced or metastatic cancer targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK molecular alterations1/2175June 2014
NCT02650401Study of RXDX-101 in children with recurrent or refractory solid tumors and primary CNS tumors180December 2015
NCT02048488/
2013–000686–37
A phase I/IIa open-label, dose escalation and cohort expansion trial of oral TSR-011 in patients with advanced solid tumors and lymphomasTSR-011TrkA, ALK1/2150October 2012
NCT02637687Oral TRK inhibitor LOXO-101 for treatment of advanced pediatric solid or primary central nervous system tumorsLOXO-101TrkA, TrkB, TrkC136December 2015
NCT02122913Oral TRK inhibitor LOXO-101 for treatment of advanced adult solid tumors1108April 2014
NCT02576431Study of LOXO-101 in subjects with NTRK fusion positive solid tumors2151October 2015
NCT01639508Cabozantinib in patients with RET fusion-positive advanced non-small cell lung cancer and those with other genotypes: ROS1 or NTRK fusions or increased MET or AXL activityCabozantinib
(XL184)
TrkA, RET, ROS1, MET, AXL268July 2012
NCT01804530Phase 1 study of PLX7486 as single agent and with gemcitabine plus nab-paclitaxel in patients with advanced solid tumorsPLX7486TrkA, TrkB, TrkC, FMS1160August 2013
NCT02279433A first-in-human study to evaluate the safety, tolerability and pharmacokinetics of DS-6051bDS-6051bTrkA,TrkB,TrkC, ROS1170September 2014
2013–003009–24Phase I-II study of F17752 in patients with advanced solid tumoursF17752ALK, ROS1, Trk1/2112September 2015
NCT02228811A study of DCC-2701 in participants with advanced solid tumorsAltiratinib
(DCC-2701)
TrkA, TrkB, TrkC, MET,
TIE2, VEGFR
148June 2014
  • ALK, anaplastic lymphoma receptor tyrosine kinase; AXL, AXL receptor tyrosine kinase; c-kit, mast/stem cell growth factor receptor; CNS, central nervous system; DDR2, discoidin domain receptor 2; Eph, ephrin receptor tyrosine kinases; FMS, McDonough Feline Sarcoma Viral; MER, MER receptor tyrosine kinase; MET, hepatocyte growth factor receptor; PDGFR, platelet-derived growth factor receptor; RET, rearranged during transfection; ROS1, ROS proto-oncogene 1; TIE2, TEK receptor tyrosine kinase; TRK, tropomyosin-related kinases (also known as TrkA,B,C for kinase A, B and C); VEGFR, vascular endothelial growth factor receptor.